BRAF is a human gene that encodes a protein called B-Raf. This gene is also known as the proto-oncogenes B-Raf and v-Raf. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, affecting cell division, differentiation and secretion. Targeted therapy plays a pivotal role in the treatment of lung cancer, and the premise of using targeted therapy is that there is a corresponding driver gene mutation, that is, a target gene mutation, so that there is a corresponding target that can receive targeted therapy. Mutations in the BRAF gene can cause disease in two ways. First, mutations can be inherited and cause birth defects. Second, mutations can appear later in life and cause cancer as oncogenes. Mutations in this gene have been found in cancers, including non-Hodgkin's lymphoma, colorectal cancer, malignant melanoma, papillary thyroid cancer, non-small cell lung cancer, lung adenocarcinoma, brain tumors and other diseases. Now, CD ComputaBio offers professional BRAF targeting services to meet your research needs.
Our Services
- Target Prediction Service
Target prediction uses specific computational methods to predict the potential targets or pharmacological effects of compounds. The small molecule compounds and inhibitors we involve can be reversely verified through target prediction. Traditional methods include methods based on orientation docking and methods based on molecular fingerprints to calculate similarity.
- In Silico Protein-Protein Interactions Prediction
Protein-protein interactions (PPIs) are highly specific physical contacts established between two or more protein molecules, including electrostatic forces, hydrogen bonds, and hydrophobic effects. Proteins rarely act alone because their functions are often regulated. We can accurately predict protein interactions based on different aspects. The services we provide mainly include:
- PPI Interaction Prediction
- PPI Interaction Network Prediction
- PPI Interaction Site Prediction
- Pharmacophore Model Construction
The construction of the pharmacophore model not only utilizes the molecular topological similarity but also the functional similarity of the groups, so that the concept of bioisosterism is used to make the model more reliable. Our pharmacophore modeling services can assist in target feasibility assessment and structure-activity relationship studies.
Our Capabilities
CD ComputaBio offers you a complete range of BRAF targeting services. We have established a complete and professional computing platform. We can help design the details of BRAF targeting services through rigorous quality control and advanced computational platforms.
Our Drug Design Strategies Targeting BRAF
- Structure-Based Drug Design, SBDD
Structure-based drug design can be applied to any drug target protein whose structure can be determined. We combine the three-dimensional structural information of the protein with computational methods to analyze the interaction patterns of ligands and receptors at the atomic level.
- Ligand-Based Drug Design，LBDD
Ligand-based drug design is to design drugs by analyzing the known ligand structures that bind to receptors when the protein structure of the drug target is not clear, including pharmacophore models, quantitative structure-activity relationship models.
Project Sample
Our computational biology team has extensive experience in the research of BRAF targets. The following is a small snapshot of our research process for reference only. For details, please feel free to consult our professional team.
* For Research Use Only.
